Drug profile · INN
eplerenone
APO-EPLERENONE
eplerenone (APO-EPLERENONE) is a mineralocorticoid receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — eplerenone
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
eplerenone (APO-EPLERENONE) is a mineralocorticoid receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Mineralocorticoid receptor antagonist
Primary target: Mineralocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is eplerenone?
eplerenone (APO-EPLERENONE) is a mineralocorticoid receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for eplerenone?
APO-EPLERENONE is a marketed brand name for eplerenone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of eplerenone?
eplerenone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.